Example：10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Cognitive decline as an outcome and marker of progression toward dementia, in early preventive trials. Alzheimer's & Dementia (IF21.566), Pub Date : 2021-09-05, DOI: 10.1002/alz.12431 Thibault Mura,Nicola Coley,Hélène Amieva,Claudine Berr,Audrey Gabelle,Pierre-Jean Ousset,Bruno Vellas,Sandrine Andrieu,
Recent Food and Drug Administration guidance endorses cognitive assessment as a possible primary endpoint for early trials for Alzheimer's disease but emphasizes the need for certainty regarding the relationship with progression to dementia.
We compared the validity of the 2-year change (Y0-Y2) of 11 markers of neuropsychological and functional abilities for the prediction of incident dementia over the following 3 years (Y2-Y5), in 860 subjects aged 70 years or older, who consulted for memory loss and were included in the "GuidAge" prevention trial.
The Free and Cued Selective Reminding Test-Free Recall (FCSRT-FR) score showed the most predictive 2-year change (area under the curve = 0.72 95% confidence interval = 0.64;0.81). Changes in other subscores of the FCSRT, verbal fluencies tasks, and composite cognitive score were also significantly predictive. Conversely, 2-year change of Mini-Mental State Examination, Trail Making test (TMT)-A, TMT-B, Clinical Dementia Rating Sum of Boxes, and Instrumental Activities of Daily Living scores did not significantly predict occurrence of dementia.
The FCSRT, the Fluency Task, and the composite cognitive score appear to be good cognitive markers of progression toward dementia in early prevention trials.